Brooklyn ImmunoTherapeutics (NYSE:BTX) Research Coverage Started at StockNews.com

StockNews.com initiated coverage on shares of Brooklyn ImmunoTherapeutics (NYSE:BTX) in a research report released on Thursday. The firm issued a hold rating on the stock.

Brooklyn ImmunoTherapeutics Price Performance

NYSE:BTX opened at $6.72 on Thursday. The firm’s fifty day moving average price is $2.01 and its 200 day moving average price is $1.35. Brooklyn ImmunoTherapeutics has a 1-year low of $6.57 and a 1-year high of $8.31. The firm has a market cap of $395.31 million, a price-to-earnings ratio of -2.96 and a beta of 4.61.

Brooklyn ImmunoTherapeutics Announces Dividend

The company also recently disclosed a monthly dividend, which will be paid on Monday, March 31st. Investors of record on Friday, March 14th will be given a $0.0862 dividend. The ex-dividend date of this dividend is Friday, March 14th. This represents a $1.03 dividend on an annualized basis and a yield of 15.38%. Brooklyn ImmunoTherapeutics’s dividend payout ratio (DPR) is -40.09%.

Brooklyn ImmunoTherapeutics Company Profile

Eterna Therapeutics, Inc is a clinical stage biopharmaceutical company, which engages in creating transformative regenerative medicine treatments for cancer, blood disorders, and monogenic diseases. It offers IRX-2, a human cell-derived cytokine therapy, studying the safety and efficacy of IRX-2 in patients with head and neck cancer in Phase 2B.